Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Brand manufacturing license sold capital city?Does imvexxy have a generic?How is abbvie's ceo allocating capital to drive r d innovation?Austedo pharmacokinetic?Tardive dyskinesia market share ingrezza austedo?
See the DrugPatentWatch profile for Ingrezza
Ingrezza (valbenazine) is used to treat tardive dyskinesia, a movement disorder that causes involuntary facial and body movements, often in people taking antipsychotic medications.
It’s prescribed to reduce involuntary movements such as lip smacking, tongue movements, grimacing, and other repetitive facial or body movements associated with tardive dyskinesia.
Ingrezza is typically used for adults with tardive dyskinesia. Patients are often identified through symptoms that persist despite changes in medication or continued use of antipsychotics.
Ingrezza’s main approved use is tardive dyskinesia. Other movement disorders may be discussed in clinical research, but the established labeled indication is tardive dyskinesia. Sources: (There were no provided sources in the prompt to cite.)
Other Questions About Ingrezza :